Mitochondrial myopathies: Diagnosis, exercise intolerance, and treatment options

Medicine and Science in Sports and Exercise

Volumn 37, Issue 12, 2005, Pages 2086-2093

  Tarnopolsky, Mark A ^a   Raha, Sandeep ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Antioxidant therapy; Electron transport chain; Free radicals; Mitochondria; Muscle

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CREATINE PHOSPHATE; CREATININE; CYTOCHROME C OXIDASE; DICHLOROACETIC ACID; DNA DIRECTED DNA POLYMERASE GAMMA; IDEBENONE; MITOCHONDRIAL DNA; PN 401; SUCCINATE DEHYDROGENASE; THIOCTIC ACID; THYMIDINE PHOSPHORYLASE; TRANSFER RNA; UBIQUINONE; UNCLASSIFIED DRUG; URIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIOGENESIS; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; CLINICAL ARTICLE; CONFERENCE PAPER; DIET SUPPLEMENTATION; EXERCISE; EXERCISE TEST; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; HYPERTROPHIC CARDIOMYOPATHY; LEBER HEREDITARY OPTIC NEUROPATHY; LEIGH DISEASE; MELAS SYNDROME; MERRF SYNDROME; MITOCHONDRIAL DNA DISORDER; MITOCHONDRIAL MYOPATHY; MNGIE SYNDROME; MYOPATHY; NEUROLOGIC DISEASE; NONHUMAN; OXYGEN CONSUMPTION; PARKINSON DISEASE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; SKELETAL MUSCLE;

ANTIOXIDANTS; EXERCISE TOLERANCE; FREE RADICALS; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MITOCHONDRIAL MYOPATHIES; MUSCLES; MUTATION;

EID: 28844465125     PISSN: 01959131     EISSN: None     Source Type: Journal    
DOI: 10.1249/01.mss.0000177341.89478.06     Document Type: Conference Paper

References (63)

1. ACUNA, C. D., G. ESCAMES, A. CARAZO, J. LEON, H. KHALDY, and R. J. REITER. Melatonin, mitochondrial homeostasis and mitochondrial-related diseases. Curr. Top. Med. Chem. 2:133-151, 2002.
2. ANDREU, A. L., M. G. HANNA, H. REICHMANN, et al. Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N. Engl. J. Med. 341:1037-1044, 1999.
3. BAILEY, D. M., I. S. YOUNG, J. MCENENY, et al. Regulation of free radical outflow from an isolated muscle bed in exercising humans. Am. J. Physiol. Heart Circ. Physiol. 287:H1689-H1699, 2004.
4. BARBIROLI, B., C. FRASSINETI, P. MARTINELLI, et al. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cell. Mol. Biol. (Noisy-le-grand). 43:741-749, 1997.
5. BARBIROLI, B., R. MEDORI H. J. TRITSCHLER, et al. Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy. J. Neurol. 242:472-477, 1995.
6. BEJMA, J., P. RAMIRES, and L. L. JI. Free radical generation and oxidative stress with ageing and exercise: differential effects in the myocardium and liver. Acta Physiol. Scand. 169:343-351, 2000.
7. BERBEL-GARCIA, A., J. R. BARBERA-FARRE, J. P. ETESSAM, et al. Coenzyme Q 10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes). Clin. Neuropharmacol. 27:187-191, 2004.
8. BERNIER, F. P., A. BONEH, X. DENNETT, C. W. CHOW, M. A. CLEARY, and D. R. THORBURN. Diagnostic criteria for respiratory chain disorders in adults and children. Neurology 59:1406-1411, 2002.
9. BORCHERT, A., E. WILICHOWSKI, and F. HANEFELD. Supplementation with creatine monohydrate in children with mitochondrial encephalomyopathies. Muscle Nerve 22:1299-1300, 1999.
10. BOURGEOIS, J., and M. A. TARNOPOLSKY. Pathology of skeletal muscle in mitochondria, disorders. Mitochondrion 4:441-452, 2004.
11. CACIC, M., E. WILICHOWSKI, V. MEJASKI-BOSNJAK, et al. Cytochrome c oxidase partial deficiency-associated Leigh disease presenting as an extrapyramidal syndrome. J. Child Neurol. 16:616-619, 2001.
12. CASEY, A., D. CONSTANTIN-TEODOSIU, S. HOWELL, E. HULTMAN, and P. L. GREENHAFF. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. Am. J. Physiol. 271:E31-E37, 1996.
13. CHAUSSAIN, M., F. CAMUS, C. DEFOLIGNY, B. EYMARD, and M. FARDEAU. Exercise intolerance in patients with McArdle's disease or mitochondrial myopathies. Eur. J. Med. 1:457-463, 1992.
14. CHEN, R. S., C. C. HUANG, and N. S. CHU. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur. Neurol. 37:212-218, 1997.
15. COLOMBO, A., E. MERELLI, P. SOLA, P. PANZETTI, D. QUAGLINO, JR., and C. FORNIERI. Mitochondrial oculoskeletal myopathy: case report. Ital J. Neurol. Sci. 9:385-389, 1988.
16. ERNSTER, L., and R. LUFT. Further studies on a population of human skeletal muscle mitochondria lacking respiratory control. Exp. Cell. Res. 32:26-35, 1963.
17. FABRIZI, G. M., R. LODI, M. D'ETTORRE, et al. Autosomal dominant limb girdle myopathy with ragged-red fibers and cardiomyopathy. A pedigree study by in vivo 31P-MR spectroscopy indicating a multisystem mitochondrial defect. J Neurol Sci. 137:20-27, 1996.
18. FISCHEL-GHODSIAN, N. Mitochondrial deafness. Ear Hear. 24:303-313, 2003.
19. GAMBELLI, S., A. MALANDRINI, F. GINANNESCHI, et al. Mitochondrial abnormalities in genetically assessed oculopharyngeal muscular dystrophy. Eur. Neurol. 51:144-147, 2004.
20. GRAY, M. W. The evolutionary origins of organelles. Trends Genet. 5:294-299, 1989.
21. GREENHAFF, P. L., K. BODIN, K. SODERLUND, and E. HULTMAN. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. Am. J. Physiol. 266:E725-E730, 1994.
22. HANISCH, F., and S. ZIERZ. Only transient increase of serum CoQ subset 10 during long-term CoQ10 therapy in mitochondrial ophthalmoplegia. Eur. J. Med. Res. 8:485-491, 2003.
23. HARRIS, R. C., K. SODERLUND, and E. HULTMAN. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin. Sci. (Lond). 83:367-374, 1992.
24. KAHARA, T., T. TAKAMURA, T. HAYAKAWA, et al. Prediction of exercise-mediated changes in metabolic markers by gene polymorphism. Diabetes Res. Clin. Pract. 57:105-110, 2002.
25. KAUFMANN, P., D. C. SHUNGU, M. C. SANO, et al. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 62:1297-1302, 2004.
26. KLOPSTOCK, T., V. QUERNER, F. SCHMIDT, et al. A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 55:1748-1751, 2000.
27. KOMURA, K., E. HOBBIEBRUNKEN, E. K. WILICHOWSKI, and F. A. HANEFELD. Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatr. Neurol. 28:53-58, 2003.
28. LUFT, R., D. IKKOS, G. PALMIERI, L. ERNSTER, and B. AFZELIUS. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J. Clin. Invest. 41:1776-1804, 1962.
29. LYNCH, D. R., G. LECH, J. M. FARMER, et al. Near infrared muscle spectroscopy in patients with Friedreich's ataxia. Muscle Nerve 25:664-673, 2002.
30. MALIK, S., H. SUDOYO, T. SASMONO, et al. Nonsyndromic sensorineural deafness associated with the A1555G mutation in the mitochondrial small subunit ribosomal RNA in a Balinese family. J. Hum. Genet. 48:119-124, 2003.
31. MATTHEWS, P. M., S. F. BERKOVIC, E. A. SHOUBRIDGE, et al. In vivo magnetic resonance spectroscopy of brain and muscle in a type of mitochondrial encephalomyopathy (MERRF). Ann. Neurol. 29: 435-438, 1991.
32. MOLNAR, M., and J. M. SCHRODER. Pleomorphic mitochondrial and different filamentous inclusions in inflammatory myopathies associated with mtDNA deletions. Acta Neuropathol. (Berl). 96:41-51, 1998.
33. MORI, M., T. YAMAGATA, T. GOTO, S. SAITO, and M. Y. MOMOI. Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS. Brain Dev. 26:453-458, 2004.
34. MURAKAMI, H., R. SOMA, J. HAYASHI, et al. Relationship between mitochondrial DNA polymorphism and the individual differences in aerobic performance. Jpn. J. Physiol. 51:563-568, 2001.
35. NEVO, Y., D. SOFFER, M. KUTAI, et al. Clinical characteristics and muscle pathology in myopathic mitochondrial DNA depletion. J. Child. Neurol. 17:499-504, 2002.
36. NICHOLLS, D. G., and S. L. BUDD. Mitochondria and neuronal survival. Physiol. Rev. 80:315-360, 2000.
37. RAHA, S., and B. H. ROBINSON. Mitochondria, oxygen free radicals, and apoptosis. Am. J. Med. Genet. 106:62-70, 2001.
38. RAHA, S., and B. H. ROBINSON. Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem. Sci. 25:502-508, 2000.
39. ROBINSON, B. H. Cell culture studies on patients with mitochondrial diseases: molecular defects in pyruvate dehydrogenase. J. Bioenerg. Biomembr. 20:313-323, 1988.
40. ROBINSON, B. H., D. M. GLERUM, W. CHOW, R. PETROVA-BENEDICT, R. LIGHTOWLERS, and R. CAPALDI. The use of skin fibroblast cultures in the detection of respiratory chain defects in patients with lacticacidemia. Pediatr. Res. 28:549-555, 1990.
41. ROSSIGNOL, R., M. MALGAT, J. P. MAZAT, and T. LETELLIER. Threshold effect and tissue specificity. Implication for mitochondrial cytopathies. J. Biol. Chem. 274:33426-33432, 1999.
42. SAITOH, S., M. Y. MOMOI, T. YAMAGATA, Y. MORI, and M. IMAI. Effects of dichloroacetate in three patients with MELAS. Neurology 50:531-534, 1998.
43. SAYDOFF, J. A., L. S. LIU, R. A. GARCIA, Z. HU, D. LI, and R. W. VON BORSTEL. Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease. Brain Res. 994:44-54, 2003.
44. SCHRAUWEN, P., and M. K. HESSELINK. Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes 53:1412-1417, 2004.
45. SCHULZ, J. B., T. DEHMER, L. SCHOLS, et al. Oxidative stress in patients with Friedreich ataxia. Neurology 55:1719-1721, 2000.
46. SHULTS, C. W., D. OAKES, K. KIEBURTZ, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59:1541-1550, 2002.
47. SINGH, G., M. T. LOTT, and D. C. WALLACE. A mitochondrial DNA mutation as a cause of Leber's hereditary optic neuropathy. N. Engl. J. Med. 320:1300-1305, 1989.
48. TAIVASSALO, T., A. ABBOTT, P. WYRICK, and R. G. HALLER. Venous oxygen levels during aerobic forearm exercise: An index of impaired oxidative metabolism in mitochondrial myopathy. Ann. Neurol. 51:38-44, 2002.
49. TAIVASSALO, T., T. D. JENSEN, N. KENNAWAY, S. DIMAURO, J. VISSING, and R. G. HALLER. The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. Brain 126:413-423, 2003.
50. TANAKA, M., H. INO, K. OHNO, et al. Mitochondrial DNA mutations in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Biochem. Biophys. Res. Commun. 174:861-868, 1991.
51. TARNOPOLSKY, M., L. STEVENS, J. R. MACDONALD, et al. Diagnostic utility of a modified forearm ischemic exercise test and technical issues relevant to exercise testing. Muscle Nerve 27:359-366, 2003.
52. TARNOPOLSKY, M. A., and G. PARISH. Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease. Muscle Nerve 22:1228-1233, 1999.
53. TARNOPOLSKY, M. A., B. D. ROY, and J. R. MACDONALD. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 20:1502-1509, 1997.
54. TARNOPOLSKY, M. A., and M. F. BEAL. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol. 49:561-574, 2001.
55. TARNOPOLSKY, M. A., D. K. SIMON, B. D. ROY, et al. Attenuation of free radical production and paracrystalline inclusions by creatine supplementation in a patient with a novel cytochrome b mutation. Muscle Nerve 29:537-547, 2004.
56. TAYLOR, R. W., T. M. WARDELL, P. M. SMITH, et al. An antigenomic strategy for treating heteroplasmic mtDNA disorders. Adv. Drug Deliv. Rev. 49:121-125, 2001.
57. THORBURN, D. R. Mitochondrial disorders: prevalence, myths and advances. J. Inherit. Metab. Dis. 27:349-362, 2004.
58. VAN BEEKVELT, M. C., B. G. VAN ENGELEN, R. A. WEVERS, and W. N. COLIER. Quantitative near-infrared spectroscopy discriminates between mitochondrial myopathies and normal muscle. Ann. Neurol. 46:667-670, 1999.
59. VAN DEN OUWELAND, J. M., P. MAECHLER, C. B. WOLLHEIM, G. ATTARDI, and J. A. MAASSEN. Functional and morphological abnormalities of mitochondria harbouring the tRNA(Leu)(UUR) mutation in mitochondrial DNA derived from patients with maternally inherited diabetes and deafness (MIDD) and progressive kidney disease. Diabetologia 42:485-492, 1999.
60. WANG, L. C., W. T. LEE, W. Y. TSAI, Y. K. TSAU, and Y. Z. SHEN. Mitochondrial cytopathy combined with Fanconi's syndrome. Pediatr. Neurol. 22:403-406, 2000.
61. WINKLER-STUCK, K., F. R. WIEDEMANN, C. W. WALLESCH, and W. S. KUNZ. Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients. J. Neurol. Sci. 220:41-48, 2004.
62. WOLF, N. I., and J. A. SMEITINK. Mitochondrial disorders: a proposal for consensus diagnostic criteria in infants and children. Neurology 59:1402-1405, 2002.
63. WONG, L. J. Comprehensive molecular diagnosis of mitochondrial disorders: qualitative and quantitative approach. Ann. N. Y. Acad. Sci. 1011:246-258, 2004.